Cell therapy and gene therapy are overlapping fields of biomedical research and treatment. Both therapies aim to treat, prevent, or potentially cure diseases, and both approaches have the potential to alleviate the underlying cause of genetic diseases and acquired diseases.
There is no single way to treat cancer. That’s why we are focused on reimagining cancer care through 4 distinct therapeutic platforms.

Tumors are masters of defense and deception, evading our immune systems with many molecular tricks. Scientists are investigating several approaches to increase the body’s immune response to cancer, including educating and activating immune cells, and exploring the role of inflammation in cancer.

Radioligand therapy combines a precision targeting compound with a therapeutic radioisotope (a radioactive particle). After administration into the bloodstream, the radioligand binds to the target cells and acts as the delivery agent for treatment via the radioisotope, which damages tumor cells, potentially disrupting their ability to replicate and/or triggering cell death, while aiming to limit damage to healthy tissue.